Deep brain stimulation is an effective treatment for obsessive–compulsive disorder but is rarely used. Action is needed by psychologists, psychiatrists and insurers so that patients with otherwise intractable cases can receive this therapy to improve their mental health.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey
Scientific Reports Open Access 17 August 2023
-
Orphan medical devices have come a long way
Orphanet Journal of Rare Diseases Open Access 05 April 2023
-
Deep brain stimulation in the ALIC-BNST region targeting the bed nucleus of stria terminalis in patients with obsessive–compulsive disorder: effects on cognition after 12 months
Acta Neurochirurgica Open Access 02 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hirschtritt, M. E. et al. J. Am. Med. Assoc. 317, 1358–1367 (2017).
Moro, E. & Cury, R. G. Moving Along 25, 6–7 (2021).
Pepper, J. et al. J. Neurosurg. 11, 1–10 (2019).
Nuttin, B. et al. Lancet 354, 1526 (1999).
Park, Y. S. et al. World. Neurosurg 126, 1–10 (2019).
US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=375533 (15 April 2022).
Davis, R. A. et al. Front. Psychiatry 12, 706181 (2021).
Nuttin, B. et al. J. Neurol. Neurosurg. Psychiatry 85, 1003–1008 (2014).
Denys, D. et al. Arch. Gen. Psychiatry 67, 1061–1068 (2010).
Luyten, L. et al. Mol. Psychiatry 21, 1272–1280 (2016).
Mosley, P. E. et al. Transl. Psychiatry 11, 190 (2021).
Provenza, N. R. et al. Nat. Med. 27, 2154–2164 (2021).
Winter, L. et al. Neuromodulation 24, 324–330 (2021).
Graat, I. et al. Biol. Psychiatry 90, 714–720 (2021).
Mallet, L. et al. N. Engl. J. Med. 359, 2121–2134 (2008).
Tyagi, H. et al. Biol. Psychiatry 85, 726–734 (2019).
Welter, M. L. et al. Biol. Psychiatry 90, e45–e47 (2020).
Kohl, S. et al. Neuromodulation 19, 542–544 (2016).
Pellegrini, L. et al. Compr. Psychiatry 108, 152246 (2021).
Pinckard-Dover, H. et al. Front. Surg. 8, 642503 (2021).
Naesström, M. et al. Surg. Neurol. Int. 8, 298 (2017).
Cormier, J. et al. Can. J. Neurol. Sci. 46, 303–310 (2019).
Acknowledgements
P.K. reports research or educational grants from the Swiss National Science Foundation (FNS 323530_177577, FNS 2020 32003BL_197709-1 and FNS 33IC30_198772), paid to his employing institution. M.S.O. has received research grants from the US National Institutes of Health (R01 NR014852, R01NS096008, UH3NS119844 and U01NS119562; training grant R25NS108939 (Principal Investigator)).
Author information
Authors and Affiliations
Contributions
Conceptualization and writing of original draft, V.V.-V. and P.A.; editing of the manuscript, V.V.-V., P.A., P.E.M., B.N., M.H. and M.S.O.; and critical revision of the manuscript, V.V.-V., P.A., P.E.M., B.D.G., R.S., N.C.M., V.V., P.K., K.D.F., H.S.M., M.F., B.H.K., M.P., E.M. J., S.C., K.M., J.C.B., H.T., P.E.H., C.B., C.H., C.K., D.D., L.Z., P.B., M.N., A.A., S.R., V.A.C., T.E.S., D.D.D., P.D., P.S., J.G., A.M.L., S.A.S., T.C., J.K., L.M., B.N., M.H. and M.S..
Corresponding author
Ethics declarations
Competing interests
V.V.-V. is a member of advisory boards and has received speaker’s honoraria from Medtronic, Boston Scientific and Abbott. P.K. reports research or educational grants from Roger de Spoelberch Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Michael J. Fox Foundation, Aleva Neurotherapeutics, Boston Scientific, Medtronic, GE Healthcare and Idorsia, paid to his employing institution; lecturing fees from Boston Scientific and Bial, paid to his employing institution; travel expenses to scientific meetings from Boston Scientific, Zambon and Abbvie. L.Z. has received honoraria for educational activities from Elekta, Boston Scientific and Medtronic. A.M.L. has consulted for Medtronic, Boston Scientific and Abbott. S.A.S. has consulted for Boston Scientific, Neuropace and Zimmer Biomet. M.S.O. serves as medical advisor for the Parkinson’s Foundation; has received research grants from Parkinson’s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation; and has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, Perseus, Robert Rose, Oxford and Cambridge. All other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Visser-Vandewalle, V., Andrade, P., Mosley, P.E. et al. Deep brain stimulation for obsessive–compulsive disorder: a crisis of access. Nat Med 28, 1529–1532 (2022). https://doi.org/10.1038/s41591-022-01879-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01879-z
This article is cited by
-
Orphan medical devices have come a long way
Orphanet Journal of Rare Diseases (2023)
-
Concerns with the promotion of deep brain stimulation for obsessive–compulsive disorder
Nature Medicine (2023)
-
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey
Scientific Reports (2023)
-
Obsessive–Compulsive Disorder and Tourette’s Disorder Symptom Presentations: Differential Diagnosis and Treatment Considerations
Current Developmental Disorders Reports (2023)
-
Deep brain stimulation in the ALIC-BNST region targeting the bed nucleus of stria terminalis in patients with obsessive–compulsive disorder: effects on cognition after 12 months
Acta Neurochirurgica (2022)